The long-term goal of PENTACON is to be an exemplar of how to combine data from model systems and humans and to utilize informatics/modeling to provide outputs that progressively realize increasingly safe and efficacious personalized medicine. Thus, we expect that the data sets and methodologies that we create will be of general interest to the scientific community. More importantly, we have the opportunity to engage in data sharing, education, and dissemination practices that set high expectations for these activities. Of course, our core dissemination activity will be the publication of excellent science related to the individualized use of NSAID drugs, complemented by providing the community with effective and user-friendly access to the underlying data, models, and systems. The importance of high-impact publications in respected journals cannot be underestimated. The participating scientists on our collaborative team have an outstanding track record in reporting high-impact science while disseminating results, data, and methods to the community. This activity will be distributed throughout the collaboration, and will be managed through the Steering Committee in conjunction with the External Advisory Committee (EAC), as described in the Administrative Core, when complex issues of authorship arise (the PENTACON website will serve as a central portal for our distribution activity). However, we recognize a need for education and dissemination beyond publication, and so propose four critical activities that will leverage the activities of PENTACON, and maximize its impact on translational science and medicine.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HL117798-01
Application #
8126752
Study Section
Special Emphasis Panel (ZGM1-PPBC-0 (GL))
Project Start
2012-08-01
Project End
2017-05-31
Budget Start
2012-08-01
Budget End
2013-05-31
Support Year
1
Fiscal Year
2012
Total Cost
$311,360
Indirect Cost
$70,307
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Okuno, Toshiaki; Gijón, Miguel A; Zarini, Simona et al. (2018) Altered eicosanoid production and phospholipid remodeling during cell culture. J Lipid Res 59:542-549
Ricciotti, Emanuela; Castro, Cecilia; Tang, Soon Yew et al. (2018) Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. Circulation 138:2367-2378
Theken, Katherine N; Grosser, Tilo (2018) Weight-adjusted aspirin for cardiovascular prevention. Lancet 392:361-362
Lin, Nan; Shay, Jessica E S; Xie, Hong et al. (2018) Myeloid Cell Hypoxia-Inducible Factors Promote Resolution of Inflammation in Experimental Colitis. Front Immunol 9:2565
Li, Xinzhi; Ballantyne, Laurel L; Crawford, Mackenzie C et al. (2018) Isoform-Specific Compensation of Cyclooxygenase (Ptgs) Genes during Implantation and Late-Stage Pregnancy. Sci Rep 8:12097
Ocana, Jesus A; Romer, Eric; Sahu, Ravi et al. (2018) Platelet-Activating Factor-Induced Reduction in Contact Hypersensitivity Responses Is Mediated by Mast Cells via Cyclooxygenase-2-Dependent Mechanisms. J Immunol 200:4004-4011
Grosser, Tilo; Naji, Ali; FitzGerald, Garret A (2018) Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment. Circ Res 122:537-539
Liu, Tianyun; Ish-Shalom, Shirbi; Torng, Wen et al. (2018) Biological and functional relevance of CASP predictions. Proteins 86 Suppl 1:374-386
Hao, Huifeng; Hu, Sheng; Wan, Qing et al. (2018) Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury. Arterioscler Thromb Vasc Biol 38:1115-1124
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575

Showing the most recent 10 out of 91 publications